enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
enGene Holdings Inc.NASDAQ: ENGN
Depreciation & Amortization · Q2 FY2026 · quarter ended Apr 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $180K rose 69.8% year over year, behind the +79.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +69.8% toward the trailing-twelve-month pace of +79.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 509K USD
- Year-over-year change
- +57.6%
- 4-year CAGR
- +17.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 509K | +57.6% |
| FY2024 | 2024-10-31 | 323K | +84.6% |
| FY2023 | 2023-10-31 | 175K | -26.5% |
| FY2022 | 2022-10-31 | 238K | -12.5% |
| FY2021 | 2021-10-31 | 272K | — |
Depreciation & Amortization vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +79.6% is the 3rd highest of 10, against a peer median of +0.9%.
- Over three fiscal years its annual growth of +28.8% compares with a peer median of +0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $3.75M USD | -7.8% | +14.7% | 97.6% | |
| LTM Mar 2026 | $3.14M USD | +14181.8% | -37.6% | — | |
| LTM Dec 2025 | CHF 2.5M CHF | +15.5% | +0.4% | 69.9% | |
| LTM Mar 2026 | $2.17M USD | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $674K USD | +14.4% | +24.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K USD | +79.6% | +28.8% | — |
| LTM Mar 2026 | $326K USD | +176.0% | — | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| LTM Mar 2026 | $97.21K USD | -103.3% | -0.7% | 0.0% | |
| Peer median (excluding ENGN) | — | +0.9% | +0.4% | 83.0% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 435K | 116K | 3.45M | 5.32M | 9.65M |
| Change in Working Capital | (1.04M) | 2.17M | (517K) | 95K | 9.74M |
| Accounts Receivables | 295K | 143K | (1.01M) | 2.01M | (595K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 110K | (197K) | 373K | 474K | 4.94M |
| Other Working Capital | (1.44M) | 2.23M | 117K | (2.39M) | 5.39M |
| Other Non-Cash Items | 7.79M | 4.34M | 72.07M | 1.12M | (1.83M) |
| Operating Cash Flow | (15.98M) | (17.59M) | (24.74M) | (48.28M) | (99.24M) |
| Capital Expenditures | (248K) | (153K) | (318K) | (925K) | (1.49M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (125.03M) | (160.84M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 137.19M |
| Other Investing Activities | 1K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (247K) | (153K) | (318K) | (125.95M) | (25.14M) |
| Debt Repayment | 7.07M | 28.39M | 33.27M | 13.06M | (699K) |
| Common Stock Issued | 14K | 12K | 56.89M | 260.15M | 2.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (144K) | (423K) | (4.01M) | (7.49M) | 0 |
| Financing Cash Flow | 22.53M | 27.97M | 86.15M | 265.72M | 1.52M |
| Effect of Forex Changes | 98K | (805K) | 1K | 1K | 1K |
| Net Change in Cash | 6.39M | 9.42M | 61.09M | 91.48M | (122.85M) |
| Free Cash Flow | (16.23M) | (17.75M) | (25.06M) | (49.21M) | (100.72M) |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.